



World Health Organization
Regional Office
for the Western Pacific

Manila, 19–21 February 2019

WHO Informal Consultation on a Framework for Scabies Control

Meeting report

WHO Informal Consultation on a Framework for Scabies Control

Meeting report

World Health Organization Regional Office for the Western Pacific
Manila, 19–21 February 2019



WHO informal consultation on a framework for scabies control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines, 19–21 February 2019: meeting report

ISBN 978-92-4-000806-9 (electronic version)

ISBN 978-92-4-000807-6 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO informal consultation on a framework for scabies control, World Health Organization Regional Office for the Western Pacific, Manila, Philippines, 19–21 February 2019: meeting report. Geneva: World Health Organization; 2020. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Abbreviations and acronyms	v
Executive summary	vi
1. Background to the meeting	1
2. Infection, disease and transmission	1
3. Mapping and surveillance	3
3.1 Background evidence	3
3.2 Mapping and surveillance: discussion, recommendations and research priorities	3
3.2.1 Identifying locations for mapping	3
3.2.2 Strategy for rapid mapping	4
3.2.3 Target population and sampling strategy	6
3.2.4 Estimation of prevalence	7
3.2.5 Research priorities	7
4. Control strategies	8
4.1 Background evidence	8
4.2 MDA thresholds and targets: discussion, recommendations and research priorities	10
4.2.1 Threshold above which MDA is recommended	10
4.2.2 Target threshold for stopping MDA	10
4.2.3 Research priorities	11
4.3 Control strategies above the MDA threshold: discussion, recommendations and research priorities	11
4.3.1 Medication choice and dosing	11
4.3.2 Number and frequency of rounds	13
4.3.3 Coverage and implementation units	14
4.3.4 Adjunctive approaches to control	14
4.3.5 Research priorities	14
4.4 Control strategies below the MDA threshold: discussion, recommendations and research priorities	15
4.4.1 Discussion and recommendations	15
4.4.2 Research priorities	15
4.5 Epidemics and outbreaks: discussion, recommendations and research priorities	16
4.5.1 Discussion and recommendations	16
4.5.2 Research priorities	16
4.6 Additional considerations for control: discussion, recommendations and research priorities	16
4.6.1 Integration	16
4.6.2 Community engagement	17
4.6.3 Cost	17

4.6.4	Safety	17
4.6.5	Human resources and training	18
4.6.6	Research priorities	18
5.	Monitoring and evaluation of programmes	19
5.1	Discussion	19
5.2	Research priorities	19
6.	Highest priorities for research	20
6.1	Choice of strategy and implementation of MDA	20
6.2	Mapping, monitoring and evaluation	20
6.3	Highest priorities	20
	References	21
	Annex 1. Case study: Ethiopia	23
	Annex 2. Summaries of presentations	24
	Annex 3. Agenda of the meeting	32
	Annex 4. List of participants	34

Abbreviations and acronyms

AIM	azithromycin–ivermectin mass drug administration
DALY	disability-adjusted life–year
IACS	International Alliance for the Control of Scabies
IDM	intensified disease management
IU	implementation unit
MDA	mass drug administration
M&E	monitoring and evaluation
NTD	neglected tropical disease
SHIFT	Skin Health Intervention Fiji Trial

Executive summary

In 2017, the Strategic and Technical Advisory Group of the WHO Department of Control of Neglected Tropical Diseases recommended that the department add scabies to its portfolio. The recommendation was made to respond to the high burden of scabies and its complications, particularly in areas with limited access to health care, and in the light of new public health control strategies for reducing the burden. The Group also recommended that, before large-scale activities for prevention and control were initiated, the prevalence of the disease should be mapped, research should be conducted to improve control, scabies should be added as an indication for use of ivermectin, guidelines should be developed for use of the medicine in public health, and affordable access to avermectins should be secured. Scabies has now been added as an indication for ivermectin to the WHO Model List of Essential Medicines, regional attempts have been initiated to map the disease burden, and, in partnership with national health ministries, studies are being conducted to provide evidence as a basis for recommendations on control. Work is under way to ensure access to medications, in the absence of adequate resources.

In order to find agreement on common strategies and to identify research priorities for a global control strategy, an informal WHO consultation was organized to discuss a framework for scabies control. The meeting took place at the WHO Regional Office for the Western Pacific in Manila, Philippines. The consultation resulted in recommendations for mapping and control strategies, research priorities and programmatic needs. Although an informal consultation does not have the authority to set WHO guidelines, the recommendations in this document represent the views of many experts, and a review of current data could therefore be considered a reasonable basis for a complete framework for scabies control. Once sufficient data are available, the framework could result in guidelines to be reviewed in the rigorous WHO process. The scabies control community should adapt its work as the framework evolves. This document should guide direction of resources to common priorities and ensure that common strategies are evaluated and updated as the evidence evolves.

The recommendations made during the informal consultation can be found in the text. The main recommendations are listed below.

1. Map the burden of scabies

Although the burden of scabies has been estimated in some countries, significant gaps remain in understanding the global distribution of the disease and its contribution to the burdens of impetigo, skin and soft-tissue infections, glomerulonephritis and possibly rheumatic heart disease. Two types of mapping were recommended: rapid mapping to generate approximate estimates of disease burden and, more importantly, identify areas that should be considered for mass treatment strategies; and detailed mapping of prevalence to refine the estimates, confirm conclusions reached by rapid mapping and identify sites for longitudinal impact assessment. Prevalence mapping would be based on the diagnostic criteria of

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24493

